Xu is passionate about understanding information and knowledge related to biopharma industry. She is bilingual in Mandarin and English. Prior to this, Xu worked as a medical writer and wrote publications based on data from clinical trials for a wide range of therapeutic areas for global pharmaceutical companies. She holds a Master degree in Medical Pharmaceutical Science from University of Groningen and a PhD degree in Biomedical Science from Vrije Universiteit Amsterdam in the Netherlands.
Latest from Xu Hu
Following the recent acceptance of a China NDA for first-in-class drug denifanstat for acne in China, Ascletis has announced positive topline results from an open-label Phase III trial focusing on the product’s long-term safety.
Newly revised regulations for the implementation of China’s Drug Administration Law transition to a market authorization holder/product-centered regulatory approach in response to the rapidly changing biopharma environment.
HUTCHMED sees good potential for its Syk inhibitor in autoimmune setting following positive topline Phase III results, with China NDA planned in first half.
Following Ribo Life Science’s recent Hong Kong IPO, an investor shares views with Scrip on the prospects for China's siRNA developers and likely deal trends in 2026.
Novo Nordisk talks about opportunity for obesity deals, Bayer looks for precision medicines and Boehringer Ingelheim tries to make big pharma small, plus more from day four of J.P. Morgan.
Plus deals involving SciNeuro/Novartis, Prazer/J&J, Haisco/AirNexis, Daiichi Sankyo/Genesis, AbbVie/Zelgen, ASK Pharm/Adlai Nortye, Harbour BioMed/Yantai Lannacheng, Hansoh/Hengrui and more.